Literature DB >> 23781974

Screening for cognition and behaviour changes in ALS.

Sharon Abrahams1, Judith Newton, Elaine Niven, Jennifer Foley, Thomas H Bak.   

Abstract

This study presents the Edinburgh Cognitive and Behavioural ALS Screen (ECAS), developed for ALS patients with physical disability for use by health care professionals. The screen is designed to detect the specific profile of cognition and behaviour changes in ALS and to differentiate it from other disorders. Forty-eight ALS patients (none with evident dementia), 40 healthy controls and 20 carers were recruited. The ECAS, a 15-20-min screen, includes an ALS-Specific score (executive functions and social cognition; fluency; language); an ALS Non-specific score (memory; visuospatial functions); and a carer behaviour screen of five domains characteristic of frontotemporal dementia (FTD). Data from healthy controls produced abnormality cut-offs of 77/100 ALS-Specific score; 24/36 ALS Non-specific score; 105/136 ECAS Total. Twenty-nine percent of patients showed abnormal ALS-Specific scores, and 6% also showed abnormal ALS Non-specific scores. The most prevalent deficit occurred in language functions (35%) followed by executive functions and fluency (23% each). Forty percent of carers reported behaviour change in at least one domain, while 15% met criteria for possible FTD. In conclusion, the ECAS is an effective within-clinic assessment for ALS that determines the presence, severity and type of cognitive and/or behavioural changes, an essential first step to managing these symptoms.

Entities:  

Mesh:

Year:  2013        PMID: 23781974     DOI: 10.3109/21678421.2013.805784

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  111 in total

1.  Disease progression in C9orf72 mutation carriers.

Authors:  Mary K Floeter; Bryan J Traynor; Jennifer Farren; Laura E Braun; Michael Tierney; Edythe A Wiggs; Tianxia Wu
Journal:  Neurology       Date:  2017-06-14       Impact factor: 9.910

2.  Apathy and its impact on patient outcome in amyotrophic lateral sclerosis.

Authors:  J Caga; S Hsieh; E Highton-Williamson; M C Zoing; E Ramsey; E Devenney; R M Ahmed; M C Kiernan
Journal:  J Neurol       Date:  2017-11-30       Impact factor: 4.849

3.  Eye-tracking controlled cognitive function tests in patients with amyotrophic lateral sclerosis: a controlled proof-of-principle study.

Authors:  Jürgen Keller; Martin Gorges; Hannah T Horn; Helena E A Aho-Özhan; Elmar H Pinkhardt; Ingo Uttner; Jan Kassubek; Albert C Ludolph; Dorothée Lulé
Journal:  J Neurol       Date:  2015-06-05       Impact factor: 4.849

4.  Neurofilaments in pre-symptomatic ALS and the impact of genotype.

Authors:  Michael Benatar; Joanne Wuu; Vittoria Lombardi; Andreas Jeromin; Robert Bowser; Peter M Andersen; Andrea Malaspina
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2019-08-21       Impact factor: 4.092

5.  Changing epidemiology of motor neurone disease in Scotland.

Authors:  Danielle J Leighton; Judith Newton; Laura J Stephenson; Shuna Colville; Richard Davenport; George Gorrie; Ian Morrison; Robert Swingler; Siddharthan Chandran; Suvankar Pal
Journal:  J Neurol       Date:  2019-02-25       Impact factor: 4.849

6.  Neurochemical correlates of functional decline in amyotrophic lateral sclerosis.

Authors:  Ian Cheong; Dinesh K Deelchand; Lynn E Eberly; Małgorzata Marjańska; Georgios Manousakis; Gaurav Guliani; David Walk; Gülin Öz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-11-22       Impact factor: 10.154

7.  Measuring reliable change in cognition using the Edinburgh Cognitive and Behavioural ALS Screen (ECAS).

Authors:  Christopher Crockford; Judith Newton; Katie Lonergan; Caoifa Madden; Iain Mays; Meabhdh O'Sullivan; Emmet Costello; Marta Pinto-Grau; Alice Vajda; Mark Heverin; Niall Pender; Ammar Al-Chalabi; Orla Hardiman; Sharon Abrahams
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2017-12-07       Impact factor: 4.092

8.  Longitudinal predictors of caregiver burden in amyotrophic lateral sclerosis: a population-based cohort of patient-caregiver dyads.

Authors:  Tom Burke; Orla Hardiman; Marta Pinto-Grau; Katie Lonergan; Mark Heverin; Katy Tobin; Anthony Staines; Miriam Galvin; Niall Pender
Journal:  J Neurol       Date:  2018-02-02       Impact factor: 4.849

9.  Perfusion alterations converge with patterns of pathological spread in transactive response DNA-binding protein 43 proteinopathies.

Authors:  Pilar M Ferraro; Charles Jester; Christopher A Olm; Katerina Placek; Federica Agosta; Lauren Elman; Leo McCluskey; David J Irwin; John A Detre; Massimo Filippi; Murray Grossman; Corey T McMillan
Journal:  Neurobiol Aging       Date:  2018-04-17       Impact factor: 4.673

10.  Identification of compound heterozygous variants in OPTN in an ALS-FTD patient from the CReATe consortium: a case report.

Authors:  Cyril Pottier; Evadnie Rampersaud; Matt Baker; Gang Wu; Joanne Wuu; Jacob L McCauley; Stephan Zuchner; Rebecca Schule; Christin Bermudez; Sumaira Hussain; Anne Cooley; Marielle Wallace; Jinghui Zhang; J Paul Taylor; Michael Benatar; Rosa Rademakers
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2018-03-20       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.